Knee Replacement Clinical Trials

Clinical trials related to Knee Replacement Procedure

Perineural Dexamethasone Versus Perineural Dexmedetomidine as Adjuvants to Ropivacaine in iPACK and Adductor Canal Blocks for Total Knee Arthroplasty: A Randomized, Double-Blind, Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This randomized, double-blind, controlled trial is designed to compare the analgesic efficacy and safety of perineural dexamethasone versus perineural dexmedetomidine as adjuvants to ropivacaine for ultrasound-guided interspace between the popliteal artery and the capsule of the posterior knee (iPACK) and adductor canal blocks in patients undergoing primary unilateral total knee arthroplasty (TKA). Elderly participants scheduled for elective TKA will be randomized into three parallel groups: ropivacaine alone (control), ropivacaine combined with perineural dexamethasone, or ropivacaine combined with perineural dexmedetomidine. The primary objective is to determine whether the addition of either adjuvant reduces postoperative opioid consumption compared with ropivacaine alone and to assess potential differences in analgesic efficacy between the two adjuvants. Secondary outcomes include pain intensity at rest and during mobilization, time to first rescue analgesia, quality of early functional recovery, and the incidence of adverse events, including postoperative nausea and vomiting, motor impairment, and hemodynamic instability.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Maximum Age: 100
Healthy Volunteers: f
View:

• Age ≥ 65 years

• Scheduled for primary unilateral total knee arthroplasty under standardized anesthetic protocol

• ASA physical status II-III (or I-III, zależnie jak planujesz)

• Ability to understand the study procedures and provide written informed consent

Locations
Other Locations
Poland
Poznan University of Medical Sciences
RECRUITING
Poznan
Contact Information
Primary
Malgorzata Reysner, MD PhD
mreysner@ump.edu.pl
+48 61 873 83 03
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2027-01-31
Participants
Target number of participants: 96
Treatments
Active_comparator: Control
Patients receive ultrasound-guided iPACK block and adductor canal block (ACB) on the operative limb with ropivacaine 0.2% alone, without any perineural adjuvant.
Experimental: Perineural Dexamethasone
Patients receive ultrasound-guided iPACK and ACB with ropivacaine 0.2% combined with perineural dexamethasone.
Experimental: Perineural Dexmedetomidine
Patients receive ultrasound-guided iPACK and ACB with ropivacaine 0.2% combined with perineural dexmedetomidine.
Sponsors
Leads: Poznan University of Medical Sciences

This content was sourced from clinicaltrials.gov